Compare BridgeBio Pharma Inc (BBIO) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Skyworks Solutions Inc — how do they compare? BridgeBio Pharma Inc trades at $82.34 (market cap $16.46B), while Skyworks Solutions Inc trades at $56.53 (market cap $8.51B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 5.02% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SWKS | |
|---|---|---|
Market Cap | $16.46B | $8.51B |
Sector | Health | Technology |
52-Week High | $90.17 | $83.40 |
52-Week Low | $44.81 | $52.50 |
Enterprise Value | $18.02B | $8.28B |
Dividend Yield | — | 5.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Skyworks Solutions (SWKS) trades at $58.24, down 3.51% amid bearish technical signals, though recent earnings beats and a 60% analyst buy rating suggest underlying strength. The company maintains solid fundamentals with $4.09B revenue and 8.93% net margin, while expanding into AI and EV markets through recent product launches. Cash flow trends show variability, with 2025 net cash flow negative at -$207M after positive flows in prior years.
The stock presents a value opportunity with consensus price target of $72.56 offering 25% upside, supported by dividend yield above 4% and strategic positioning in growing semiconductor segments. Key risks include ongoing legal investigations and customer concentration, but strong analyst support and technical oversold conditions near support at $55 indicate potential for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
